An official website of the United States government
Home
Name
Phesgo
Alternate names
None
Primary Site
Breast
Histology
None
Radiation
None
Remarks
6/29/2020 The FDA approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer. Patients should be selected based on an FDA-approved companion diagnostic test.
Note: Pertuzumab and trastuzumab are immunotherapy while hyaluronidase-zzxf is an ancillary drug. Code this regimen as BRM/Immunotherapy.
Note: Pertuzumab and trastuzumab are immunotherapy while hyaluronidase-zzxf is an ancillary drug. Code this regimen as BRM/Immunotherapy.
Drugs for Phesgo
Name
Alternate Names
Omnitarg
Perjeta
R1273
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Cytostatic agent--tyrosine kinase inhibitor
Humanized monoclonal antibody
NSC Number
900005
Primary Site
Breast
Histology
None
Remarks
JANUARY 2013 IMPORTANT UPDATE: This drug has changed categories. A comprehensive review has been completed and in keeping with the FDA, Pertuzumab is to be coded as a Biologic therapy/Immunotherapy agent. Effective with diagnosis date January 1, 2013 forward, code pertuzumab as BRM/Immunotherapy. For cases diagnosed prior to January 1, 2013 continue coding this drug as chemotherapy.
FDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.
Perjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.
FDA approved Perjeta June 8, 2012 to treat HER2-positive late-stage (metastatic) breast cancer.
Perjeta is also used in combination with trastuzumab and docetaxel for neoadjuvant treatment of patients with HER2-positive locally advanced, inflammatory, or early stage breast cancer (either TS >2cm or node positive) as part of a complete treatment regimen for early breast cancer.
Coding
This drug should be coded
Name
Alternate Names
KADCYLA
T-DM 1
TDM 1
Trastuzumab-MCC-DM1 antibody conjugate
Trastuzumab-MCC-DM1 Immunoconjugate
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Antibody-drug conjugate
NSC Number
None
Primary Site
Metastatic HER-2 breast cancer
Histology
None
Remarks
May 3, 2019: FDA approved ado-trastuzumab emtansine (KADCYLA) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.
February 22, 2013: Kadcyla received FDA approval for the treatment of metastatic HER-2 positive breast cancer in patients that had previously been treated with trastuzumab and a taxane, either separately or in combination.
February 22, 2013: Kadcyla received FDA approval for the treatment of metastatic HER-2 positive breast cancer in patients that had previously been treated with trastuzumab and a taxane, either separately or in combination.
Coding
This drug should be coded
